Ivacaftor-d9

• CAT Number: S000127
• CAS Number: 1413431-07-8
• Molecular Formula: C24H19D9N2O3
• Molecular Weight: 401.55
• Purity: ≥95%
• Target: CFTR
• IUPAC Name: N-[2-tert-butyl-4-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-5-hydroxyphenyl]-4-oxo-1H-quinoline-3-carboxamide
• InChI: InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)/i4D3,5D3,6D3
• InChIKey: PURKAOJPTOLRMP-ASMGOKTBSA-N
• SMILES: [2H]C([2H])([2H])C(C1=C(C=C(C(=C1)C(C)(C)C)NC(=O)C2=CNC3=CC=CC=C3C2=O)O)(C([2H])([2H])[2H])C([2H])([2H])[2H]

Ivacaftor-d9 (CAS: 1413431-07-8), a high-quality pharmaceutical research compound designed for advanced studies in cystic fibrosis and respiratory research. As a deuterated analog of Ivacaftor, it offers enhanced stability and improved pharmacokinetic properties. Ivacaftor-d9 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for cystic fibrosis. Trusted by leading laboratories, Ivacaftor-d9 is your go-to solution for cutting-edge respiratory research. Unlock new possibilities in cystic fibrosis treatment with Ivacaftor-d9, where innovation meets reliability.

Reference

[1]. Scott L Harbeson, et al. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development. J Pharmacol Exp Ther. 2017 Aug;362(2):359-367.
[Content Brief]